Literature DB >> 15751243

Clinical outcome and subjective quality of life after photodynamic therapy in patients with age-related macular degeneration.

F Krummenauer1, M Braun, H B Dick.   

Abstract

PURPOSE: Whereas the efficacy of photodynamic therapy (PDT) in preventing the progression of age-related macular degeneration (ARMD) is established, its effect on quality of life is under discussion.
METHODS: All patients who underwent PDT during 2000 and 2001 at the University Eye Hospital of Mainz were interviewed using a standardized 82-item questionnaire on quality of life and patient satisfaction in ophthalmologic patients. Information was assessed in terms of 82 questions; global scores ranging from 1.0 (optimum self-estimated quality of life) to 4.0 (worst) were derived. Cataract patients' scores were used to characterize the ARMD patients' subjective outcome; the latter were then related to clinical outcome parameters via logistic regressions.
RESULTS: A total of 84 patients (50% female, median age 77 years) were interviewed, who underwent a median of three PDT interventions. During the period of PDT treatment, their median decrease in visual acuity was 3 lines from 0.125 to 0.063. Patients who reported a subjective increase in visual function during this period showed a median private flexibility score of 1.86; patients with the subjective impression of visual function decrease, a median score of 2.71; the median scores for mobility were 2.00 versus 3.00, for flexibility in reading 1.91 versus 3.64, for psychological stress 1.56 versus 2.25, and for communicational flexibility 1.72 versus 2.25. The difference in reading flexibility was statistically significant (p=0.001) after correction for clinical cofactors.
CONCLUSIONS: The established clinical benefit of PDT treatment concerning its efficacy in ARMD progression prevention coincides with an at least slight subjective benefit in quality of life and patient satisfaction. However, the latter is associated with the patients' subjective impression of visual acuity progression rather than with clinically validated outcome after PDT treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15751243     DOI: 10.1177/112067210501500112

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  7 in total

1.  Influence of photodynamic therapy for age related macular degeneration upon subjective vision related quality of life.

Authors:  Alex W Hewitt; V Swetha Jeganathan; Juanita E Kidd; Konrad Pesudovs; Nitin Verma
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-01-13       Impact factor: 3.117

Review 2.  Verteporfin: a review of its use in the management of subfoveal choroidal neovascularisation.

Authors:  Caroline Fenton; Caroline M Perry
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

3.  [Photodynamic therapy of AMD for the first (better sight) and the second (worse sight) eyes].

Authors:  A C Marti; F K P Sutter; D Barthelmes; J C Fleischhauer; M M Kurz-Levin; M M Bosch; H Helbig
Journal:  Ophthalmologe       Date:  2007-02       Impact factor: 1.059

4.  A cell membrane-targeting AIE photosensitizer as a necroptosis inducer for boosting cancer theranostics.

Authors:  Niu Niu; Ying Yu; Zhijun Zhang; Miaomiao Kang; Lei Wang; Zheng Zhao; Dong Wang; Ben Zhong Tang
Journal:  Chem Sci       Date:  2022-04-19       Impact factor: 9.969

5.  Determinants of patient satisfaction with photodynamic therapy for neovascular age-related macular degeneration or polypoidal choroidal vasculopathy.

Authors:  Kenji Yamashiro; Akitaka Tsujikawa; Akihiro Nishida; Yasuo Kurimoto
Journal:  Jpn J Ophthalmol       Date:  2007-10-05       Impact factor: 2.447

6.  Quality of life in age-related macular degeneration: a review of available vision-specific psychometric tools.

Authors:  Robert P Finger; Monika Fleckenstein; Frank G Holz; Hendrik P N Scholl
Journal:  Qual Life Res       Date:  2008-05       Impact factor: 4.147

Review 7.  Enhancement of Photodynamic Cancer Therapy by Physical and Chemical Factors.

Authors:  Mingying Yang; Tao Yang; Chuanbin Mao
Journal:  Angew Chem Int Ed Engl       Date:  2019-07-10       Impact factor: 15.336

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.